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Lipids are categorized according to their biological function.  Phospholipids, 
glycolipids, and cholesterol are bulk membrane lipids that offer structure and 
support to the cells and organelle membranes.  Signaling lipids include 
diacylglycerol, phosphatidic acid, and lysophosphatidic acid (LPA).  These are 
low abundance lipids that are active in various pathways.  LPA acts through 
GPCR receptors to activate G or beta mediated stimulation of phospholipase C 
leading to phosphatidylinositol-(4,5)-bisphosphate hydrolysis, Gi mediated 
inhibition of adenyl cyclase, and Gi mediated stimulation of the mitogenic Ras-
MAP kinase.  To further elucidate the biological activity of LPA and potentially 
identify new LPA binding receptors, activity based protein profiling (ABPP) can 
be utilized to label and identify enzymes.  This thesis discusses the development 
of an LPA activity probe which incorporates a benzophenone group that can be 
photocrosslinked to a protein via ultraviolet radiation and a secondary azide tag 
to facilitate purification of the probe and bound protein. 
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Chapter 1:  Introduction 
Lipids compose the cell membrane and help maintain cell structure.  This 
was discovered by Gorter and Gendell in 1925 when they performed experiments 
with chromocytes and found the cells were surrounded by a lipid layer two 
molecules thick.1  For over 50 years, the biological roles of lipids were thought to 
be limited to composing membrane bilayers and acting as intermediates in lipid 
biosynthesis.2  However, it was later discovered that lipids play more extensive 
roles in physiological function than originally thought.  It is now known that lipids 
play key roles in signal transduction and are intermediates in numerous important 
biological pathways. 
Diacylglycerol is the first known lipid second messenger.  Its role as a 
second messenger was proved by Hokin and Hokin in 1950 when they 
discovered that acetyl or carbamylcholine caused an early turnover of inositol 
phospholipids.2  This discovery, along with Nishizuka uncovering that membrane 
lipids activate cyclic nucleotide-independent kinase activity, and the revelation 
that negatively charged phospholipids replaced membrane components as 
kinase activators, indicated that lipids are more involved in eukaryotic cell 
biochemistry than previously thought.2-3  Furthermore, lipids are involved in 
organelle biogenesis and can regulate intracellular protein dynamics by binding 







Lipids can be broken down into two main categories: bulk membrane lipids 
and signaling lipids.  Three major types of membrane lipids are phospholipids, 
glycolipids, and cholesterol.  Examples of phospholipids are phosphatidylcholine, 
phosphatidylinositol, phosphatidylserine, and phosphatidylethanolamine.  These 
lipids, along with cholesterol, compose the bulk of the cell membrane.  Low 
abundance signaling lipids such as phosphatidic acid, diacylglycerol, the 
phosphatidylinositol polyphosphates, and lysophosphatidic acid function as 
signaling lipids that regulate biological processes.4  A key role of these lipids is to 
recruit peripheral proteins to the cell membrane in a spatiotemporally specific 
manner.5 
Membranes of cellular components are not uniformly composed of lipids.  
Lipid type and concentration are dependent on local lipid metabolism and 
regulated lipid transport.5a  For example, plasma membranes, endosomes, and 
trans-Golgi network membranes maintain transbilayer asymmetry by actively 
transporting particular types of lipids from one opposing leaflet to another.5a  
Originally, it was thought that specific localization of peripheral proteins would 
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require protein–protein interactions because protein–lipid interactions were not 
expected to be sufficiently specific.5a  However, this idea was refuted when it was 
determined that subcellular localization behaviors of peripheral proteins can best  
be elucidated by analyzing the kinetics and energetics of their binding to model 
membranes, as long as the membranes mimic the cellular membrane to which it 
is targeted.5a 
Peripheral proteins are composed of one or more modular domains 
specialized in lipid binding.  These include pleckstrin homology (PH), epsin 
amino terminal homology (ENTH), and Tubby domains along with many others.6  
Some peripheral proteins, such as phospholipase A2, do not contain separate 
protein binding domains, but instead utilize their own molecular surface or an 
amphipathic secondary structure.5a  Other proteins are post-translationally 
modified through the attachment of lipid anchors that embed them in the lipid 
bilayer.  A prominent example involves the Ras GTPases, which have been 
implicated in cancer.  Initial protein–lipid binding is mediated by electrostatic 
interactions between anionic lipid surfaces and cationic protein surfaces.5a  In 
addition to the role of recruiting proteins to the plasma membrane, lipids such as 
lysophospholipids act as intercellular mediators.  Intercellular lipid mediators act 
via membrane receptors or nuclear receptors known as corticosteroids in order to 





Background and Significance 
The initial indication that lysophosphatidic acid 6a plays a more extensive 
role than just being an intermediate in intracellular lipid biosynthesis came when 
it was found to induce smooth muscle contraction.8  LPA research began in the 
1990s with the discovery that LPA is mitogenic and signals through various G 
protein-coupled receptors (GPCR).9  LPA is now known to act as an extracellular 
lipid mediator that produces growth factor-like responses in a wide range of cells. 
LPA is a lysolipid.  Lysolipids possess the distinguishing characteristic in 
that they only contain one acyl chain located at either the sn-1 or sn-2 position.  
LPA is composed of a single acyl chain located at the sn-1 position, a glycerol 
backbone, and a phosphate headgroup (Figure 2).  It is the smallest and 
structurally simplest glycerophospholipid.10  For a long time, the origins of 
extracellular LPA production were unclear until it was determined that autotaxin 
(ATX) and phospholipase D (PLD) were the same enzyme that catalyzed LPA 
production.10-11  Autotaxin (ATX) was discovered in melanoma cell culture and 
was found to increase melanoma cell motility.12  PLD and ATX cleave the choline 
group from lysophosphatidylcholine (LPC), producing LPA (Figure 2).  
LPA is produced by several cell types including mature neuron cells, 
Schwann cells, adipocytes, and fibroblasts.13  Production of the lysolipid by these 
cells is the source of LPA found in serum, saliva, and follicular fluid.9  In addition,  
LPA is also produced in ovarian cancer cells, glioblastomas, and melanoma 




LPA is synthesized in the aforementioned cell lines by two methods: the removal 
of a fatty acid acyl chain from phosphatidic acid by phospholipase A1 (PLA1) or 
phospholipase A2, or the removal of a choline group from phosphatidylcholine, 
as shown in Figure 2.8 
In phospholipase A1 production of LPA, PLA1 releases the fatty acid chain 
from the sn-1 position of membrane phospholipids, producing sn-2 and 
polyunsaturated isoforms of LPA that interact with LPA receptor 3.14  Type II 
secretory phospholipase A2 (sPLA2) removes an acyl chain from the sn-2 
position but is not capable of producing hydrolyzed lipids in intact cell 
membranes, resulting in low levels of LPA in the plasma.  However, sPLA2 is 
capable of selectively hydrolyzing lipids in damaged cells and microvesicles that 
are released during apoptosis and by cancer cells, and are found in large 









LPA and Autotaxin Relationship 
 
The protein autotaxin (ATX) was first discovered in melanoma cell culture 
and has been found to stimulate cancer cell motility, angiogenesis, and cell 
proliferation, indicating that it may be pivotal in cancer biology.15  It is a member 
of the nucleotide pyrophosphatase/phosphodiesterase family of enzymes.12a  
ATX is a type II integral membrane protein that contains a single transmembrane 
domain, two somatomedin B-like domains, and a catalytic domain.16  The highest 
levels of ATX/PLD mRNA are expressed in kidney, brain, lung, intestine, and 
ovary cells.  
ATX production of LPA is of biological importance because it plays key 
roles in various pathways.  ATX utilizes LPC as a substrate, which exists at high 
concentrations in many bodily fluids. The resulting product, LPA, stimulates 
cellular responses such as malignant cell proliferation and LPA autocrine control 
of adipose tissue.  The fact that autotaxin stimulation in malignant cell 
proliferation is increased in the presence of LPC provides evidence that LPA is a 
signaling component in cell proliferation.  The proposed mechanism of cancer 
cell motility involves activation through GPCR LPA1.12a  In addition to the role it 
plays in cell proliferation, ATX-induced LPA production also results in the 
differentiation of adipocytes and adipocyte cell lines.  ATX has been shown to be 
upregulated in genetically obese mice.  These two facts, along with studies 
showing that LPA exists in extracellular fluid of adipose cells and is released in 
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vitro by adipocytes, imply that LPA paracrine control of adipose tissue could be 
mediated by ATX.17 
LPA signaling 
LPA activity is receptor-mediated with the lipid interacting with at least 
three G protein-coupled receptors that belong to the endothelial differentiation 
gene subfamily, which traverses the membrane seven times.9 The first receptor 
to be discovered was LPA1, which is the most widely expressed LPA receptor 
with high mRNA levels in the colon, intestine, pancreas, small intestine, and 
heart.8-9  High levels of this receptor are also present in the cerebral cortical 
ventricular zone during neurogenesis and in adult oligodendrocytes and 
Schwann cells.8   
After its discovery, two other LPA receptors known as LPA2 and LPA3 
were identified.  LPA2 and LPA3 are not as widely distributed as LPA1 but are 
overexpressed in cancer cells, indicating their role in the disease.  Recently, 
three other LPA receptors were identified.18  One receptor known as LPA4 is 
unique in the fact that it does not belong to the EDG family, but is most similar to 
the purinergic family, which means LPA may have a greater biochemical role 
than previously thought.9  While there is not enough evidence to support LPA4 
activation of phopholipase C and adenylyl cyclase, circumstantial evidence 
suggests that the receptor may tentatively mediate the activity of these enzymes. 
LPA receptors are known to couple to three subfamilies of G proteins 
known as Gα, Gi, and G12/13.9  These three major receptors share high homology 
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in amino acid sequences in all areas except for the C-terminal region.9  The 
extent of carboxyl tail homology between the LPA1 and LPA2 receptors is 27% 
with the LPA2 and LPA3 receptors having only 17% homology.19  Since all other 
domains have the same homology, the ability of the receptors to effect biological 
change must stem from the different amino acid sequences located in the 
carboxyl terminal region.19-20  Evidence to prove the specificity of the carboxyl 
terminal region has been found from studies published by Xu et al., in which a 
yeast two-hybrid screen was utilized to identify TRIP6 as a LPA2 receptor 
interacting protein.19 
Major signaling routes for LPA include: G or beta mediated stimulation of 
phospholipase C leading to phosphatidylinositol-(4,5)-bisphosphate hydrolysis, Gi 
mediated inhibition of adenyl cyclase, Gi mediated stimulation of the mitogenic 
Ras-MAP kinase, Gα and G12/13 mediated activation of small GTPase RhoA, 
which regulates cytoskeletal movement, and finally Gi activation of 
phosphoinositide-3-kinase, Rac, and PKB/Akt to promote cell movement and 
suppress cell death.9  LPA also signals through second messenger pathways 
and activates the Ras and Rho family of GTPases.9  The Ras and Rho GTPase 
cycles include GDP and GTP bound states.  GTP binding is promoted by specific 
GDP–GTP exchange factors in which GTP bound forms can react with various 
downstream effectors producing changes in the cellular environment.8 
All mammalian cells, tissues, and organs with the exception of the liver 
express LPA receptor subtypes of the EDG family, which indicates that LPA 
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signaling occurs in a cooperative manner.  However, the identity of the LPA 
receptor subtype that couples each known G protein-coupled receptor is 
unknown.  All three receptors can mediate PLC activation, inhibition of cyclic 
adenosine monophosphate (cAMP) accumulation, and activation of mitogen-
activated protein kinase (MAPK) pathway, but different isoforms of LPA have a 
different efficacy and potency for each receptor, thus triggering downstream 
events.  LPA2 exhibits the highest affinity of all the receptors for LPA and 
couples more efficiently to neovascularizing factors with LPA1 having a bigger 
effect on cell motility events.8 
Ras MAP Kinase Signaling 
LPA-induced activation of Ras involves the GES, SOS, and intermediate 
protein tyrosine kinase dependent activity.  According to studies, Ras activation 
is not a direct linear pathway such as Gi-tyrosine kinase-Ras-GTP, but instead it 
involves exchange factors and cell-type dependent, mutually opposing, GTPase 
activating proteins.9  One proposed method of signaling suggests that LPA and 
other GPCR agonists act through the epidermal growth factor receptor to trigger 
mitogenic signaling.  In this transactivation model, a GPCR activated 
metalloprotease cleaves the epidermal growth factor (EGF) precursor at the cell 
surface to stimulate EGFR signaling.  However, the transactivation model is not 






Cytoskeletal organization is mediated through Rho GTPases.  Three well 
studied GTPases are RhoA, Cdc42, and Rac.  LPA activation of RhoA proceeds 
via G12/13 subunits that bind to three distinct Rho-specific guanine nucleotide 
exchange factors, promoting RhoA-GTP accumulation and activation of 
downstream Rho-Kinase, which initiates cell rounding, retraction, and endothelial 
tight junction opening.9 
LPA as an intracellular messenger 
It is currently well known that LPA is an intermediate in phospholipid 
biosynthesis, which takes place in the endoplasmic reticulum.  During this 
process, LPA is formed from glycerol-3-phosphate by acyl-CoA and then further 
acylated to phosphatidic acid.  Evidence may suggest that LPA has another role 
in the body besides just being an intermediate in lipid biosynthesis.  High 
concentrations of LPA can compete with synthetic lipid found within the cell to 
bind to the nuclear transcription factor peroxisome proliferator-activated receptor 
gamma (PRAR-γ).  However, it is unclear how extracellular LPA could cross the 
membrane, since it would be rapidly dephosphorylated by membrane-bound lipid 
phosphatases.  Furthermore, if extracellular LPA found its way to the cytosol, it is 
still unclear how the lipid would be able to reach the nucleus.  Thus, new studies 








Logically, LPA must be degraded in mammalian cells in order to maintain 
cell functionality.  Extracellular LPA is degraded by phosphate group removal to 
produce inactive monoacylglycerol.9  In addition, a family of membrane ecto 
enzymes has been identified whose members mediate dephosphorylation of LPA 
and other lipid phosphatases.  This group of enzymes is known as lipid 
phosphate phosphohydrolases (LPP).  LPPs belong to a superfamily of 
hydrolases that includes bacterial acid phosphatases and DGPPase that contain 
three highly conserved domains.  Unlike phospholipase C, LPP does not 
dephosphorylate water-soluble phosphate esters and appears to have a 
substrate similar to phosphatidic acid, indicating that it competes with 
phosphatidic acid (PA) for LPA dephosphorylation.  However, more studies are 
needed in order to confirm their ability to degrade lysophosphatidic acid. 
Activity Based Protein Profiling  
As evidenced by the information obtained from the text above, LPA has 
extensive biological and pathophysiological roles.  Much remains to be learned 
about the pathways in which LPA is active and the proteins that it targets.  With 
the advent of genome sequencing, an array of information about the proteins 
present in eukaryotic organisms has been obtained.  Genomic techniques such 
as chromosomal translocation, transcriptional profiling, and RNA interference–
gene silencing have given insights into the physiological roles of proteins.21   
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However, genomic techniques cannot convey other important information 
about protein function, including regulation caused by small molecule binding and 
post-translational protein modification.  To efficiently elucidate protein function at 
this level, a range of sophisticated proteomics have been developed.  Within the 
field of proteomics, basic techniques such as gel electrophoresis and mass 
spectrometry have been extended to devise powerful techniques such as  
multidimensional protein identification technology (MudPIT) and isotope coded 
affinity tags (ICAT), yeast two–hybrid systems, and protein microarrays that 
generate more information about quantitative differences in protein abundance 
and protein interactions.22  However, these methods are not able to probe 
proteins in vivo, which is disadvantageous because variation in activity caused by 
small molecule binding and post-translational modification cannot be detected.22b  
Probes have been developed that specifically target enzyme families.  In addition 
to binding already characterized enzyme classes, ABPP probes used in 
conjunction with streptavidin chromatography, gel separation, and mass 
spectrometry analysis can identify and assign biological function to novel 
proteins.22a 
The strategy of activity based protein profiling (ABPP) was developed in 
order to characterize proteins based on activity rather than abundance.  ABPP is 
a chemical proteomic method that utilizes active site-directed probes to visualize 
changes in protein activity located in cells and tissues.  Although recent 
advances in genomic sequencing have brought more attention to the utility of 
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ABPP, the first stages of ABPP began over a century ago.21  ABPP is ideal for 
targeting an array of enzyme families since probes can be constructed that 
incorporate mechanism-based inhibitors, protein-reactive natural products, and 
general electrophiles.21  Currently, probes have been developed for more than a 
dozen enzyme classes, including proteases, kinases, and phosphatases.  
General probe design incorporates a reactive group by which the probe is 
selectively cross-linked to targets, as well as a secondary tag bound by a linker.  
Common reporter tags are rhodamine, azide, alkyne, and biotin.  An illustration of 











The principal aim of ABPP is the synthesis of small probes that can 
covalently label enzyme active sites.  Ideally, probes must be able to target a 
wide array of enzymes, but since numerous nucleophilic residues without 
catalytic activity exist within the proteome, cross-reactivity with such residues 
must be avoided in order to prevent jeopardizing ABPP studies.23  This can be 
achieved by combining reactive and binding groups that target conserved 
mechanistic or structural features in enzyme active sites.23  Reactive groups can 
be either electrophilic and modify active sites or photoaffinity groups that label 
targets upon UV irradiation.23   
Once the probe has labeled target proteins via reaction with active site 
residues, purification of the successfully labeled proteins is facilitated by the 
secondary reporter tag on the probe.  Reporter tags such as alkynes and azides 
can undergo click reactions that allow the probe to be biotinylated and then 
purified via a streptavidin column.  Examples of probes that have been currently 
utilized in activity based protein profiling are given in Figure 4.  In addition to the 
probes drawn in Figure 4, Cravatt and colleagues have designed a series of 
probes that target the serine hydrolases.  These probes, termed 
fluorophosphonate reagents (shown in Figure 5) have been derivatized with a 
number of linkers and a reporter tag such as rhodamine or biotin in order to 
visualize and characterize catalytically active serine hydrolases in proteomes.22b  
These probes have shown great selectivity for labeling active serine hydrolases 






























































The great reactivity of these probes stems from an electrophilic center that 
is primed for covalent reaction with a highly nucleophilic oxygen atom of serine 
and the near-tetrahedral structure of the fluorophosphonate (FP) groups, which 
mimic the enzyme substrate tetrahedral intermediate.  Craik and Mahrus 
synthesized a series of probes with complementary reactivity to the 
fluorophosphonate probes.22b  These probes incorporate a diphenyl phosphonate 
electrophile and substrate mimicking recognition groups that promote selective 
recognition.   
Once probes have been synthesized, they can be utilized to study protein  
interactions through a variety of different methods.  One platform that exists is gel 
electrophoresis.  This method incorporates the use of fluorescent probes in 
conjunction with biotinylated probes.  Fluorescent probe labeled proteomes are 
distinguished by 1D or 2D polyacrylamide gel electrophoresis.  Then, biotinylated 
probes can be used along with streptavidin affinity chromatography, gel 
separation, and mass spectrometry in order to purify the labeled probes.  Another 
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method that offers higher resolution than gel electrophoresis is liquid 
chromatography–mass spectrometry (LC–MS).23   
LC–MS can be divided into two categories.  The first category consists of 
experiments that analyze protein targets of probes.  The second deals with those 
that specifically analyze probe-labeled peptides derived from these targets.  The 
first method is essentially a combination of ABPP and MudPIT.  The procedure 
involves incubating biotinylated probes with streptavidin beads to enrich probe 
labeled proteins.  Incubation is then followed by trypsin digestion and the 
enriched proteins are analyzed by LC–MS.  This process is capable of detecting 
50–100+ enzyme activities but does not offer a straightforward way of identifying 
probe labeled peptides of enzyme targets.  To overcome this disadvantage, 
active site peptide profiling (ASPP) can be used.  ASPP involves digesting probe 
treated proteomes with trypsin prior to incubation. Probe labeled peptides are 
enriched using either streptavidin or antibody resins followed by analysis with 
LC–MS.21   
In order to obtain the information that ABPP and ASPP offers, Speers and 
Cravatt developed tandem orthogonal proteolysis–ABPP (TOP–ABPP).21  Even 
though advancements in resolution and information gleaned from ABPP have 
occurred, methods that involve LC–MS are still not desirable due to the large 
sample volume that is required in order to run an analysis.  Ideally, an ABPP 
procedure will eventually be produced that offers the high resolution of LC–MS 
along with the minimal sample requirement of gel electrophoresis.  Progress has 
18 
 
been made towards this goal by combining capillary electrophoresis coupled with 
laser-induced fluorescence.  However, more work needs to be done in order to 
achieve a method which produces high resolution with minimal sample 
requirement.21  
ABPP is currently utilized in biological experiments such as target 
discovery, inhibitor discovery, and enzyme active site characterization.  ABPP is 
a suitable method for target discovery because it can account for protein 
regulation via small molecule binding and post-translational modification.  
Inhibitor discovery involves utilizing the probe as a competitor in which inhibitors 
are then identified by their ability to block probe labeling of enzymes.  This 
strategy negates the need for recombinant expression and purification because 
enzyme tests can be conducted within the proteome.  In addition, the probe acts 
as a substitute for substrate analysis resulting in the ability to detect enzymes 
that may not be detectable via other methods.  Finally, with the ability to label 
new enzyme active sites, ABPP is an avenue to characterize new enzymes that 









Chapter 2:  Research Design 
The main focus of my research has been the development of the LPA 
activity probe shown in Figure 6.  The synthetic route chosen for production of 
the activity probe involved the incorporation of a benzophenone group and an 
azide tag.  Proteins that bind the LPA backbone can be cross-linked to the probe 
through irradiation of the photoaffinity group with ultra-violet light.  The azide can 
then be used to label cross-linked adducts via click chemistry.  The probe, along 
with bound proteins, can then be purified via a streptavidin column. The activity 





















The first synthetic route (shown in Figure 7) to the target compound began 
by protecting the free alcohol of (S)-glycerolacetonide with tert-butyldiphenylsilyl 
chloride to produce 2 (Figure 7).  After acetal deprotection with 90% acetic acid 
to 3, a monomethoxytrityl protecting group was selectively installed on the 
primary hydroxyl group to yield 4.  This was followed by incorporation of a p-
methoxybenzyl chloride protecting group to generate 5.  However, 6 was not 
obtained in high yield, and reproducibility was problematic.  A better synthetic 
route (shown in Figure 8) was then developed in which the order of protecting 
group installation was switched.  The first step of the synthesis involved 
protecting the free alcohol of 1 with a p-methoxybenzyl protecting group, followed 
by acetal deprotection to yield 9.  After this step, the primary alcohol of 9 was 
selectively protected by monomethoxytrityl chloride (MMT) followed by 
incorporation of a tert-butyldiphenylsilyl protecting group to yield 11.  Finally, the 
MMT group was deprotected producing the free alcohol 12. 
Incorporation of the benzophenone cross-linking group and azide tag 
(shown in Figure 9) began with the coupling of 4-benzoylbenzoic acid to Z-N-
Boc-L-lysine methyl ester to produce 14.  Trifluoroacetic acid deprotection yielded 
the free amine 15, which was converted into azide 16 using 0.01 M copper 
sulfate solution, 0.804 M potassium carbonate solution and imidazole-1-sulfonyl 
azide. Once the azide was purified, the methyl ester was hydrolyzed using 2 M 
sodium hydroxide and methanol to yield 17.  Coupling of the acid to methyl 6-
aminohexanoate yielded 19 upon ester hydrolysis with 2 M sodium hydroxide 
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and ethanol (Figure 10).  Following this reaction, 19 and 12 underwent a coupling 
reaction to produce 20.  After purification, the benzyl-protected phosphoramidite 
was installed following p-methoxybenzyl deprotection with DDQ to yield 22.  The 
free phosphate was then produced with trimethylsilyl bromide.  Finally, the lipid 
intermediate was deprotected with tetrabutylammonium fluoride to produce the 
target LPA probe 23. 
Conclusion 
The best synthethic route to produce a novel LPA activity probe involved 
protecting the free alcohol of (S)-glycerolacetonide with p-methoxybenzyl 
chloride.  After acetal deprotection, MMT and TBDPS groups were selectively 
installed.  This was necessary in order to produce 12 with a free alcohol at the 
sn-1 position.  The next synthetic strategy involved producing an acyl chain 
which incorporated a benzophenone cross-linking group and an azide label that 
would facilitate purification of the probe and bound protein.  Synthesis of the 
derivatized acyl chain began with a lysine analog and was achieved in seven 
steps yielding 19.  Next, 12 and 19 were coupled together to produce 20.  After 
installing a dibenzyl protected phospharamidite, 23 was achieved in 61% yield 
following TMSBr and TBAF deprotection to produce an LPA activity probe that 







































































































































































































































General.  All reagents were purchased from Aldrich, Acros, or ChemImpex and 
used as received.  Dry solvents were obtained from a Pure Solv solvent delivery 
system purchased from Innovative Technology, Inc.  Column chromatography 
was performed using 230–400 mesh silica gel purchased from Sorbent 
Technologies.  NMR spectra were obtained using a Varian Mercury 300 
spectrometer and a Bruker Avance 400 spectrometer.  Mass spectra were 
obtained with a MALDI-TOF spectrometer.  Optical rotation values were obtained 




Sodium hydride (518 mg, 12.1 mmol) was dissolved in 40 mL N,N-
dimethylformamide at 0 °C under nitrogen.  Compound 7 (1 mL, 8.1 mmol) was 
dissolved in 40 mL N,N-dimethylformamide and added slowly over 10 minutes to 
the sodium hydride solution.  After complete addition of 7, the reaction was 
stirred at 0 °C for 1 h, then p-methoxybenzyl chloride (1.64 mL, 12.1 mmol) was 
added.  The mixture was stirred for 18 h at room temperature.  After the reaction 
was complete, water (50 mL) was added to quench the reaction.  The mixture 
was then extracted with dichloromethane and saturated sodium chloride (2 x 50 
mL).  The organic phase was then dried with magnesium sulfate, filtered, and 
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then concentrated.  Column chromatography on silica gel and a gradient solvent 
system of 10–50% ethyl acetate/hexanes afforded 8 as a clear oil (1.51 g, 74%).  
NMR data matched that in the literature.24 
 
(R)-3-(4-methoxybenzyloxy)propane-1,2-diol (9) 
Compound 8 (1.51 g, 5.9 mmol) was dissolved in methanol (59 mL), and p-
toluenesulfonic acid (181 mg, 0.95 mmol) was added to the solution.  The 
reaction was stirred at room temperature for 24 h.  The reaction was quenched 
with sodium bicarbonate (110 mg, 1.3 mmol) and extracted with water and 
dichloromethane (2 x 50 mL).  The organic phase was dried with magnesium 
sulfate, filtered, and concentrated.  Column chromatography on silica gel and a 
gradient solvent system of 50% methanol/ethyl acetate and 100% methanol 
produced 9 (661 mg, 52%) as a clear oil. 




Diol 9 (661 mg, 3.1 mmol) was dissolved in pyridine (31 mL) under nitrogen.  4-
methoxytrityl chloride (1.91 g, 6.2 mmol), 4-dimethylaminopyridine (381 mg, 0.31 
mmol), and molecular sieves were added.  The reaction was stirred at room 
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temperature for 24 h.  After the reaction was complete, the mixture was filtered 
over Celite to remove the molecular sieves and concentrated.  Column 
chromatography on silica gel and a gradient solvent system of 10–50% ethyl 
acetate/hexanes and 100% ethyl acetate afforded 10 as a clear oil (1.33 g, 88%). 




Alcohol 10 (408 mg, 0.84 mmol) was dissolved in pyridine (8 mL) under nitrogen.  
To the mixture was added imidazole (114 mg, 1.7 mmol), t-butyldiphenyl 
chlorosilane (437 µL, 1.7 mmol), and molecular sieves.  The reaction was stirred 
at room temperature for 18 h.  The mixture was then filtered over celite to remove 
the molecular sieves and concentrated.  Chromatography on silica gel with a 
gradient solvent system of 10–25% ethyl acetate/hexanes afforded 11 (600 mg, 











Compound 11 (599 mg, 0.83 mmol) was dissolved in methanol:dichloromethane 
(33 mL 2:1).  Camphorsulfonic acid (96 mg, 0.414 mmol) was added.  The 
reaction was stirred at room temperature for 3.5 h after which it was neutralized 
by triethylamine and concentrated.  Chromatography on silica gel with a gradient 
solvent system of 25–35% ethyl acetate/hexanes afforded 12 (113 mg, 31%).  




Compound 13 (400 mg, 1.0 mmol) was dissolved in methanol (11 mL), and 10% 
palladium hydroxide (40 mg) by weight was added.  The mixture was placed 
under hydrogen and stirred for 24 h at room temperature.  After the 24-h period, 
the reaction was filtered over Celite.  The filtrate was concentrated, and the 
remaining traces of solvent were removed.  The residue was then dissolved in 
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N,N-dimethylformamide (6.7 mL) and placed under nitrogen.  N-
methylmorpholine (390 µL, 3.5 mmol), along with 4-benzylbenzoic acid (229 mg, 
1.1 mmol), EDCl (233 mg, 1.2 mmol), and 4-dimethylaminopyridine (149 mg, 1.2 
mmol) was added.  The reaction was stirred for 5 h at room temperature.  After 
completion, the reaction was concentrated.  Column chromatography on silica 
gel with a solvent gradient system of 50% ethyl acetate/hexanes afforded 14 

























(S)-methyl 6-amino-2-(4-benzoylbenzamido)hexanoate (16) 
Compound 14 (343 mg, 0.71 mmol) was dissolved in dichloromethane (5.9 mL).  
Trifluoroacetic acid (5.9 mL) was added, and the solution was stirred at room 
temperature for 2.5 h.  After completion, the solvent was removed, and the 
residue (15) was placed under vacuum for 24 h.  The residue was then dissolved 
in methanol (7.5 mL), and imidazole-1-sulfonyl azide hydrochloride (177 mg, 0.8 
mmol), 0.804 M potassium carbonate solution (1.4 mL, 1.2 mmol), and 0.01 M 
copper(II) sulfate pentahydrate solution (707 µL, 0.007 mmol) were added.  The 
reaction was stirred at room temperature for 3.5 h.  After completion, the reaction 
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was extracted with ethyl acetate and 2 M hydrochloric acid.  The organic phase 
was dried with magnesium sulfate and concentrated.  Column chromatography 
on silica gel with a solvent gradient of 50% ethyl acetate/hexanes afforded 16 
(208 mg, 75%).  NMR data matched that in the literature.25 
 
(S)-6-azido-2-(4-benzoylbenzamido)hexanoic acid (17) 
Compound 16 (276 mg, 0.7 mmol) was dissolved in methanol (12.3 mL), and 2 M 
sodium hydroxide (12.3 mL) was added.  The reaction was stirred at room 
temperature for 1 h.  After completion, the reaction was extracted with 2 M 
hydrochloric acid.  The organic layer was dried with magnesium sulfate and 
concentrated to yield 17 (266 mg, 99%).  The residue was passed on without 
further purification.  NMR data matched that in the literature.25 
 
(R)-methyl 6-(6-azido-2-(4-benzoylbenzamido)hexanamido)hexanoate (18) 
Compound 17 (239 mg, 0.628 mmol) was dissolved in dichloromethane (11.4 
mL), placed under nitrogen, and 4-dimethylaminopyridine (99 mg, 0.817 mmol) 
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was added.  Methyl 6-aminohexanoate hydrochloride (148 mg, 0.817 mmol) was 
dissolved in dichloromethane (11.4 mL) and N-methylmorpholine (691 mL, 6.28 
mmol) was added.  The solution was combined with 17 dissolved in 
dichloromethane, and EDCl (156 mg, 0.817 mmol) was added.  The reaction was 
stirred at room temperature for 18 h.  Column chromatography on silica gel with a 
solvent gradient of 35–75% ethyl acetate/hexanes afforded 18 (273 mg, 88%). 
1H NMR (300 MHz, CDCl3 ) δ 1.37 (dd, J = 14.94, 7.91 Hz, 2H), 1.61 (m, 8H), 
1.83 (d, J = 7.32 Hz, 1H), 2.0 (m, 1H), 2.30 (t, J = 7.32 Hz, 2H), 3.28 (m, 4H), 
3.65 (s, 3H), 4.68 (q, J = 7.04 Hz, 1H), 6.62 (m, 1H), 7.50 (t, J = 7.46 Hz, 2H), 
7.62 (t, J = 7.40 Hz, 1H), 7.78 (d, J=8.30 Hz, 2H), 7.83 (d, J=8.12 Hz, 2H), 7.94 
(dd, J = 8.17 Hz, 2H);  13C NMR (300 MHz CDCl3) δ 191.58, 170.86, 168.26, 
166.05, 166.01, 136.55, 132.54, 129.71, 129.67, 128.35, 128.07, 126.73, 53.11, 
51.14, 50.71, 38.96, 33.34, 31.88, 28.58, 28.55, 28.16, 25.84, 25.82, 23.91, 
22.37;  MALDI-HRMS [M + Na]+  calcd:  530.2374 found:  530.2394;  [α]D296K = 
+0.21 (c 6.5, 1:4 methanol/chloroform) 
 
 
(R)-6-(6-azido-2-(4-benzoylbenzamido)hexanamido)hexanoic acid (19) 
Compound 18 (303 mg, 0.598 mmol) was dissolved in ethanol (3 mL) and 2 M 
sodium hydroxide (3 mL) was added.  The solution was stirred at room 
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temperature for 1 h.  Once the reaction was complete, the solution was extracted 
with dichloromethane and 2 M hydrochloric acid (2 x 30 mL).  The organic phase 
was dried with magnesium sulfate and concentrated to yield 19 (272 mg, 93%).  
The residue was used in the next reaction. 
 
Compound 12 (320 mg, 0.6 mmol) was dissolved in dichloromethane (11 mL) 
under nitrogen. N,N-dicyclohexylcarbodiimide (173 mg, 0.84 mmol) and 4-
dimethylaminopyridine (103 mg, 0.84 mmol) were added.  The mixture was 
stirred at room temperature for 20 minutes.  Compound 19 (396 mg, 0.84 mmol) 
was then added in 10 mL dichloromethane, and the reaction was stirred at room 
temperature for 24 hours.  Once the reaction was complete, the mixture was 
concentrated.  Column chromatography on silica gel with a solvent gradient 
system of 35–75% ethyl acetate/hexanes afforded 20 as a clear oil (596 mg, 
99%). 
1H NMR (300 MHz, CDCl3) δ 1.04 (s, 9H), 1.28 (m, 2H), 1.51 (m, 8H), 1.94 (m, 
2H), 2.11 (m, 2H), 3.26 (m, 4H), 3.40 (d, J = 4.86 Hz, 2H), 3.79 (s, 3H), 4.11 (m, 
3H) 4.69 (s,2H), 6.74 (s, 1H), 6.82 (d, J = 8.30 Hz, 2H), 7.11 (d, J = 8.35 Hz, 2H), 
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7.40 (m, 6H), 7.50 (d, J=7.90 Hz, 2H), 7.59 (d, J=7.61 Hz, 1H), 7.65 (t, J = 7.68 
Hz, 4H), 7.78 (d, J =8.30 Hz, 2H), 7.83 (d, J=8.12 Hz, 2H), 7.94 (d, J = 8.17 Hz, 
2H);  13C NMR (300 MHz CDCl3) δ 195.80, 173.25, 171.18, 168.59, 166.37, 
146.02, 140.31, 136.84, 135.80, 135.78, 133.61, 132.87, 130.06, 129.61, 129.15, 
127.63, 127.51, 127.47, 127.09, 113.62, 72.80, 70.86, 70.19, 66.06, 55.21, 
53.45, 51.04, 39.38, 33.67, 32.28, 29.00, 28.51, 26.80, 26.24, 24.16, 22.71, 
19.25;  MALDI-HRMS [M + Na]+  calcd:  948.4338 found:  948.4330;  [α]296KD = 

























Compound 20 (147 mg, 0.159mmol) was dissolved in dichloromethane (5 mL) 
and 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) (90 mg, 0.398 mmol) was 
added.  Following completion (4.5 h), the reaction was extracted with 10% 
sodium carbonate and dichloromethane (2 x 30 mL).  The organic phase was 
38 
 
dried with magnesium sulfate and concentrated.  Column chromatography on 
silica gel with a solvent gradient of 40–75% ethyl acetate/hexanes and 100% 
ethyl acetate/hexanes afforded 21 as a clear oil (91.7 mg, 78%).  
1H NMR (300 MHz, CDCl3) δ 1.07 (s, 9H), 1.29 (m, 2H), 1.52 (m, 8H), 1.78 (m, 
1H), 1.97 (m, 1H), 2.15 (t, J = 7.05, 2H), 2.43 (s, 1H), 3.27 (m, 4H), 3.53 (d, J = 
3.66 Hz, 2H), 3.91 (m, 1H), 4.10 (m, 3H), 4.64 (m, 1H), 7.39 (m, 6H), 7.50 (d, 
J=7.90 Hz, 2H), 7.59 (d, J=7.61 Hz, 1H), 7.65 (d, J = 7.68 Hz, 4H), 7.78 (d, J 
=8.30 Hz, 2H), 7.83 (d, J=8.12 Hz, 2H), 7.94 (d, J = 8.17 Hz, 2H)  13C NMR (300 
MHz CDCl3) δ 145.80 145.86, 136.98, 136.84, 136.64, 135.49, 132.69, 129.89, 
128.22, 127.59, 127.45, 126.88, 71.25, 53.22, 50.86, 33.47, 32.06, 28.30, 26.66, 
22.51, 19.05, 16.62  MALDI-HRMS [M + Na]+  calcd:  828.3766, found  828.3763  































Compound 21 (100 mg, 0.124 mmol) was dissolved in dichloromethane (10 mL).  
Dibenzyl diisopropylphosphoramidite (122 µL, 0.373 mmol) and 1H-tetrazole 
(828 µL, 0.373 mmol) were added.  The reaction was stirred at room temperature 
under nitrogen for 24 h.  Then the reaction was cooled to 0 °C and mCPBA (64 
mg, 0.373 mmol) was added.  The reaction was stirred for 1 h at room 
temperature.  After completion, the solvent was concentrated and the residue 
was purified via chromatography on silica gel with a solvent gradient of 30–75% 
ethyl acetate/hexanes and 100% ethyl acetate to yield 22 (14.1 mg, 50%). 
1H NMR (300 MHz, CDCl3) δ 1.03 (s, 9H), 1.27 (m, 2H), 1.50 (m, 8H), 1.79 (m, 
1H), 1.94 (m, 1H), 3.23 (m, 4H), 3.97 (m, 5H), 4.71 (m, 1H), 4.93 (s, 4H), 7.30 
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(m, 14H), 7.48 (m, 3H), 7.62 (m, 6H), 7.78 (m, 4H), 7.96 (m, 2H)  13C NMR (300 
MHz CDCl3) δ 195.97, 173.68, 171.49, 171.48, 166.40, 140.36, 135.89, 133.21, 
133.06, 130.98, 130.16, 128.68, 128.54, 127.965, 127.949, 127.859, 127.799, 
127.28, 69.78, 69.65,, 69.49, 69.39, 67.74, 64.31, 60.50, 53.56, 51.19, 39.52, 
33.79, 32.51, 29.12, 28.66, 28.79, 26.89, 26.39, 24.42, 22.81, 21.15, 19.36, 
14.30,  MALDI-HRMS [M + Na]+  calcd:  1088.4365, found  1088.4398 [α]296KD = -




Compound 22 (0.033 mmol) was dissolved in dichloromethane under nitrogen, 
and trimethylsilyl bromide (309 µL) was added, and the reaction was run until 
completion.  After the disappearance of starting material, the solvent was 
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removed, and the residue was dissolved in methanol (5 mL).  The reaction was 
stirred at room temperature for 1 h.  The methanol was then removed.  After 
residue solvent had been removed, the product was dissolved in 5.0 mL 
tetrahydrofuran. Tetrabutylammonium fluoride trihydrate (0.327 mmol) was 
added, and the reaction was allowed to run overnight.  The next day the solvent 
was removed, and the product was purified via a reversed-phase column with a 
solvent gradient of 90–10% methanol to produce 23 (12.1 mg, 61%). 
1H NMR (300 MHz, CDCl3) δ 1.05 (m, 9H), 1.29 (m, 7H), 1.65 (m, 1H), 1.95 (m, 
1H), 2.33 (m, 1H), 3.35 (m, 4H), 3.68 (m, 1H), 4.12 (m, 1H), 7.39 (m, 2H), 7.59 
(m, 1H), 7.73 (m,2H), 7.80 (m, 2H), 8.00 (m, 2H) 13C NMR (300 MHz, CDCl3) 
196.44, 196.41, 173.86, 171.71,140.62, 137.25, 135.18, 133.53, 130.46, 130.45, 
128.90, 127.86, 127.74, 63.96, 59.15, 53.80, 39.70, 34.43, 33.36, 32.54, 29.65, 
29.14, 27.61, 24.85, 24.23, 20.07, 13.82, MALDI-HRMS [M+ Na]+ calcd:  
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